Priority Review of Drug Submissions (Therapeutic Products)
Priority Review is a fast-track status granted to eligible new drug submissions for human use, following review and approval of a request submitted by the sponsor of the drug. Priority Review submissions are introduced into Health Canada's drug review queue in accordance with an accelerated review target of 180 days.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Priority Review of Drug Submissions (Therapeutic Products)HTMLEnglish publication HTML
-
Priority Review of Drug Submissions (Therapeutic Products)HTMLFrench publication HTML
Similar records